ERBB2 and neoplasm: Differences in pharmacodynamics of the targeted NNM formulation in vivo was suggested as the reason for the improved anti-tumor effect, by enhancing intracellular drug delivery to HER2-overexpressing cancer cells (Kirpotin et al., 2006).